185 related articles for article (PubMed ID: 36551910)
1. The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy.
Jeong TJ; Lee HT; Gu N; Jang YJ; Choi SB; Park UB; Lee SH; Heo YS
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551910
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
Park UB; Jeong TJ; Gu N; Lee HT; Heo YS
Biochem Biophys Res Commun; 2022 Apr; 599():31-37. PubMed ID: 35168061
[TBL] [Abstract][Full Text] [Related]
3. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
Lu D; Xu Z; Zhang D; Jiang M; Liu K; He J; Ma D; Ma X; Tan S; Gao GF; Chai Y
Front Immunol; 2022; 13():826045. PubMed ID: 35309324
[TBL] [Abstract][Full Text] [Related]
4. Dostarlimab for the treatment of endometrium cancer and other solid tumors.
Rubio-Pérez J; Hernández R; Hernández T; Doger B; Casado V; Moreno V
Drugs Today (Barc); 2021 Mar; 57(3):187-197. PubMed ID: 33729216
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1.
Wang S; Khan FI
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445859
[TBL] [Abstract][Full Text] [Related]
6. Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays.
Dengler AF; Weiss R; Truong T; Irvin SC; Gadhia N; Hassanein M; Georgaros C; Taylor JA; Paccaly A; Sumner G; Andisik MD; Torri A; Partridge MA
AAPS J; 2021 Oct; 23(6):109. PubMed ID: 34608545
[TBL] [Abstract][Full Text] [Related]
7. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Lee HT; Lee SH; Heo YS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
11. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Cancer Therapy.
Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Lee SH; Lee HT; Lim H; Kim Y; Park UB; Heo YS
Biochem Biophys Res Commun; 2020 Jun; 527(1):226-231. PubMed ID: 32446372
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Lee JY; Lee HT; Shin W; Chae J; Choi J; Kim SH; Lim H; Won Heo T; Park KY; Lee YJ; Ryu SE; Son JY; Lee JU; Heo YS
Nat Commun; 2016 Oct; 7():13354. PubMed ID: 27796306
[TBL] [Abstract][Full Text] [Related]
15. Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor.
Liu J; Wang G; Liu L; Wu R; Wu Y; Fang C; Zhou X; Jiao J; Gu Y; Zhou H; Xie Z; Sun Z; Chen D; Dai K; Wang D; Tang W; Yang TTC
Sci Rep; 2019 Nov; 9(1):17830. PubMed ID: 31780710
[TBL] [Abstract][Full Text] [Related]
16. An Integrated Analysis of Dostarlimab Immunogenicity.
Lu S; Bowsher RR; Clancy A; Rosen A; Zhang M; Yang Y; Koeck K; Gao M; Potocka E; Guo W; Jen KY; Im E; Milton A
AAPS J; 2021 Jul; 23(5):96. PubMed ID: 34324079
[TBL] [Abstract][Full Text] [Related]
17. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
18. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
[No Abstract] [Full Text] [Related]
19. Biophysical and Immunological Characterization and
Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
Li Y; Liang X; Yang T; Guo S; Chen X
Front Oncol; 2022; 12():878054. PubMed ID: 36226060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
